Evidence highlighted the role of two-series prostaglandins in NAFLD pathogenesis, decreasing insulin secretion and pancreatic β-cell proliferation, increasing gluconeogenesis, enhancing hepatic lipogenesis, and decreasing triglyceride output, thus establishing negative effects on liver inflammation and NAFLD progression [159]. The gene discussed is INS; the disease is metabolic dysfunction-associated steatotic liver disease.